Home-based telerehabilitation is just as effective as traditional rehab for restoring arm function in stroke survivors, according to late-breaking science presented at this year’s American Stroke Association International Stroke Conference in Honolulu.

Andexanet alfa (Andexxa), the only FDA-approved reversal agent for factor Xa inhibitors, was successful in mitigating bleeding events associated with that class of anticoagulants, researchers reported Feb. 7 in the New England Journal of Medicine.

The FDA announced Feb. 6 it has approved Cablivi for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood-clotting disorder.

Hospitals participating in the second phase of a quality improvement program through the American Heart Association/American Stroke Association reduced their median door-to-needle times for acute ischemic stroke patients from 66 minutes to 51 minutes. And the program is now setting its goals even higher. 

E-cigarette users can now add stroke to the list of risks they incur when they make the choice to vape, according to a study of more than 400,000 Americans.

A study of Native Americans who experienced ischemic stroke showed they carried a high burden of risk factors, nearly all of which grew in prevalence from 2000 to 2016.

Direct oral anticoagulants (DOACs) are on their way to surpassing warfarin as the anticoagulant of choice among Medicaid beneficiaries, despite their higher cost, according to new research published in the Journal of the American College of Cardiology.

The Society for Cardiovascular Angiography and Interventions (SCAI) weighed in on the ongoing debate regarding the long-term safety of paclitaxel-coated balloons and stents on Jan. 25, largely agreeing with the FDA’s stance that the benefits of such devices appear to outweigh the risks until more information becomes available.